Praxis Precision Medicines, Inc. announced on June 22, 2026, that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) for elsunersen (PRAX-222), an antisense oligonucleotide intended to treat seizures associated with SCN2A Developmental and Epileptic Encephalopathy (DEE). The designation is supported by preliminary clinical evidence from the EMBRAVE Part A trial, a Phase 1/2 study in pediatric patients. Praxis Precision Medicines, Inc. is a biopharmaceutical company focused on the development of medicines for neurological disorders.
